These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35044255)

  • 1. Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: Application to a melanoma network.
    Freeman SC; Cooper NJ; Sutton AJ; Crowther MJ; Carpenter JR; Hawkins N
    Stat Methods Med Res; 2022 May; 31(5):839-861. PubMed ID: 35044255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian pairwise meta-analysis of time-to-event outcomes in the presence of non-proportional hazards: A simulation study of flexible parametric, piecewise exponential and fractional polynomial models.
    Freeman SC; Sutton AJ; Cooper NJ; Gasparini A; Crowther MJ; Hawkins N
    Res Synth Methods; 2024 May; ():. PubMed ID: 38772906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models.
    Freeman SC; Carpenter JR
    Res Synth Methods; 2017 Dec; 8(4):451-464. PubMed ID: 28742955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma.
    Cope S; Chan K; Campbell H; Chen J; Borrill J; May JR; Malcolm W; Branchoux S; Kupas K; Jansen JP
    Value Health; 2023 Apr; 26(4):465-476. PubMed ID: 36503035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making.
    Cope S; Jansen JP
    BMC Med Res Methodol; 2013 Dec; 13():147. PubMed ID: 24289277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.
    Quartagno M; Morris TP; Gilbert DC; Langley RE; Nankivell MG; Parmar MK; White IR
    Clin Trials; 2023 Dec; 20(6):594-602. PubMed ID: 37337728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
    Jachno K; Heritier S; Wolfe R
    BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis.
    Wiksten A; Hawkins N; Piepho HP; Gsteiger S
    Value Health; 2020 Jul; 23(7):918-927. PubMed ID: 32762994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate network meta-analysis of survival function parameters.
    Cope S; Chan K; Jansen JP
    Res Synth Methods; 2020 May; 11(3):443-456. PubMed ID: 32125077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival analysis of irish amyotrophic lateral sclerosis patients diagnosed from 1995-2010.
    Rooney J; Byrne S; Heverin M; Corr B; Elamin M; Staines A; Goldacre B; Hardiman O
    PLoS One; 2013; 8(9):e74733. PubMed ID: 24098664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.
    Wei Y; Royston P; Tierney JF; Parmar MK
    Stat Med; 2015 Sep; 34(21):2881-98. PubMed ID: 26099573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current application of the Royston-Parmar model for prognostic modeling in health research: a scoping review.
    Ng R; Kornas K; Sutradhar R; Wodchis WP; Rosella LC
    Diagn Progn Res; 2018; 2():4. PubMed ID: 31093554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A non-parametric approach for jointly combining evidence on progression free and overall survival time in network meta-analysis.
    Daly CH; Maconachie R; Ades AE; Welton NJ
    Res Synth Methods; 2022 Sep; 13(5):573-584. PubMed ID: 34898019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined test versus logrank/Cox test in 50 randomised trials.
    Royston P; Choodari-Oskooei B; Parmar MKB; Rogers JK
    Trials; 2019 Mar; 20(1):172. PubMed ID: 30885277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of methods for estimating the attributable risk in the context of survival analysis.
    Gassama M; Bénichou J; Dartois L; Thiébaut AC
    BMC Med Res Methodol; 2017 Jan; 17(1):10. PubMed ID: 28114895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2013 Dec; 13():152. PubMed ID: 24314264
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.